HOUSE_OVERSIGHT_024041.jpg
1.07 MB
Extraction Summary
1
People
2
Organizations
0
Locations
2
Events
0
Relationships
2
Quotes
Document Information
Type:
Financial report / presentation slide
File Size:
1.07 MB
Summary
This document is a page from a confidential financial report or presentation, numbered page 30, bearing a House Oversight Bates stamp. It analyzes 'Biopharma IPO Trends' from 2004 to Q1 2014, showing a significant spike in capital raised and number of IPOs in 2013 and early 2014. The text attributes this growth to the JOBS Act and 'testing the waters meetings,' suggesting a strong opportunity for investors in the healthcare technology sector.
People (1)
| Name | Role | Context |
|---|---|---|
| The Fund Managers | Investment Managers |
Mentioned in the text as believing the JOBS Act helped the biotech IPO window.
|
Organizations (2)
| Name | Type | Context |
|---|---|---|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024041'
|
|
| Biopharma |
Industry subject of the chart
|
Key Quotes (2)
"The Fund Managers believe the JOBS Act and the use of 'testing the waters meetings' has been one of the factors that helped open the current biotech IPO window"Source
HOUSE_OVERSIGHT_024041.jpg
Quote #1
"The combination of all of these positive factors has significantly strengthened the position of smaller development and early commercial stage healthcare technology companies"Source
HOUSE_OVERSIGHT_024041.jpg
Quote #2
Full Extracted Text
Complete text extracted from the document (1,266 characters)
investors to grasp the complexities and opportunities of the small biotech companies before the formal filing of their IPO registration statements, and the start of the traditional IPO road show.
The Fund Managers believe the JOBS Act and the use of “testing the waters meetings” has been one of the factors that helped open the current biotech IPO window, expanded the base of investors (public market specialist and generalist investors) participating in the recent offerings, and helped drive the after-market performance of many of these offerings.
The Fund Managers believe the JOBS Act and the use of “testing the waters meetings” has been one of the factors that helped open the current biotech IPO window, expanded the base of investors (public market specialist and generalist investors) participating in the recent offerings, and helped drive the after-market performance of many of these offerings.
Biopharma IPO Trends
($ in millions)
($ in millions)
[Chart Y-axis Left: Capital Raised ($ in millions)]
[Chart Y-axis Right: # of IPOs]
[Chart X-axis: Years 2004 - 2014 Q1]
[Chart Y-axis Right: # of IPOs]
[Chart X-axis: Years 2004 - 2014 Q1]
Data Points Visible:
2004: $754, 13
2005: $778, 15
2006: $2,028, 20
2007: $1,451, 19
2008: $0, 0
2009: $153, 2
2010: $693, 11
2011: $526, 8
2012: $769, 11
2013: $2,852, 36
2014 Q1: $1,501, 23
2004: $754, 13
2005: $778, 15
2006: $2,028, 20
2007: $1,451, 19
2008: $0, 0
2009: $153, 2
2010: $693, 11
2011: $526, 8
2012: $769, 11
2013: $2,852, 36
2014 Q1: $1,501, 23
Legend: Pre-Phase 3, Phase 3, Marketed, # of IPOs
The combination of all of these positive factors has significantly strengthened the position of smaller development and early commercial stage healthcare technology companies, and creates a unique period of opportunity for investors in the sector.
30
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024041
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024041
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document